ArticleFrontiers in immunology2026
Molecular insights into CRIP1 as an immunometabolic regulator revealed by CRIP1 knockout and single-cell transcriptomics.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cysteine-rich intestinal protein 1 (CRIP1) was first identified as a metabolism-related gene nearly four decades ago, yet its precise biological function remains poorly defined. More recently, CRIP1 has been implicated in several cancers, including hepatocellular carcinoma, acute myeloid leukemia, multiple myeloma, and melanoma, where it can act as either a pro-tumorigenic factor or a tumor suppressor. In contrast, its physiological roles under non-malignant conditions have been only minimally explored, and current understanding remains largely confined to early speculative links with zinc transport and metal ion metabolism. This is the first to comprehensively dissect the basic functions of CRIP1, addressing both immune regulation and metabolism. We first sought to define CRIP1's involvement in hepatic metabolism by analyzing liver tissues from CRIP1 knockout (KO) and wild-type (WT) mice under basal conditions, focusing on zinc transport, iron metabolism, and mitochondrial oxidative phosphorylation identified through transcriptomic analysis. In parallel, we evaluated how CRIP1 deficiency modulates metabolic and immune responses under chronic low-grade inflammation induced by oral gavage with periodontal pathogens, assessing CRIP1-dependent changes. Furthermore, we investigated the relationship between CRIP1 expression and inflammatory gene profiles using single cell RNA sequencing data of peripheral mononuclear cells from healthy individuals and periodontitis patients. By comparing pro-inflammatory and anti-inflammatory gene expression according to CRIP1 expression levels across diverse immune cell subsets, we aimed to clarify whether CRIP1 is more likely to contribute to pro-inflammatory or anti-inflammatory regulation. This integrated approach provides new insights into the fundamental immunomodulatory and metabolic role of CRIP1.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.